CTC
GMAB icon

Central Trust Company’s Genmab GMAB Stock Holding History

Central Trust Company’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385 Hold
14
– – ﹤0.01% 1540
2026
Q1 		$376 Sell
14
-3
-18% -$90 ﹤0.01% 1517
2025
Q4 		$513 Buy
17
+3
+21% +$94 ﹤0.01% 1442
2025
Q3 		$430 Buy
+14
New +$341 ﹤0.01% 1375
2024
Q4 		– Sell
-7
Closed -$173 – 1457
2024
Q3 		$173 Buy
+7
New +$187 ﹤0.01% 1404

Other funds holding GMAB

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $3.02B AUM 34.37% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
LWAM
Legacy Wealth Asset Management Woodbury, Minnesota $456M AUM 35.19% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Central Trust Company's GMAB Position: Q2 2026 in Review

Central Trust Company held its Genmab (GMAB) position steady in Q2 2026 at 14 shares worth $385. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

Central Trust Company first reported a position in GMAB in Q3 2024 and has held it in 5 quarters since. The position peaked at $513 in Q4 2025. 89 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Central Trust Company held 14 shares of Genmab worth $385 as of Q2 2026.
  • Central Trust Company left its Genmab share count unchanged in Q2 2026.
  • Genmab made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1540 holding.
  • Central Trust Company first reported a position in Genmab in Q3 2024 and has held it in 5 quarters since.
  • Central Trust Company's Genmab position peaked at $513 in Q4 2025.
  • 89 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.